Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
Year: 2017
Type: article
Abstract: primary MPN xenografts. In conclusion, we postulate that ruxolitinib-induced deficiencies in DSB repair pathways sensitized MPN cells to synthetic lethality triggered by PARP inhibitors.
Source: Blood
Authors: Margaret Nieborowska-Skorska, Silvia Maifrede, Yashodhara Dasgupta, Katherine Sullivan, Sylwia Flis, Bac Viet Le, Martyna Solecka, Elizaveta A. Belyaeva, Lucia Kubovcakova, Morgan Nawrocki, Martin Kirschner, Huaqing Zhao, Josef T. Prchal, Katarzyna Piwocka, Alison R. Moliterno, Mariusz Wasik, Steffen Koschmieder, Tony R. Green, Radek C. Skoda, Tomasz Skorski
Institutions: Temple University, Narodowy Instytut Leków, Instytut Biologii Doświadczalnej im. Marcelego Nenckiego, University of Pennsylvania, University of Basel, University Hospital of Basel, RWTH Aachen University, University of Utah, Johns Hopkins University, Wellcome/MRC Cambridge Stem Cell Institute, University of Cambridge
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Brigham and Women's Hospital, Wellcome Trust, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Cancer Research UK, National Institute for Health and Care Research, European Commission, Narodowe Centrum Nauki, Children's Hospital of Michigan, National Institutes of Health, Medical Research Council, National Cancer Institute
OpenAlex ID: W2765195183